CN103230566B - Traditional Chinese medical composition for treating cholecystitis cholelithiasis and application thereof - Google Patents

Traditional Chinese medical composition for treating cholecystitis cholelithiasis and application thereof Download PDF

Info

Publication number
CN103230566B
CN103230566B CN201310136671.6A CN201310136671A CN103230566B CN 103230566 B CN103230566 B CN 103230566B CN 201310136671 A CN201310136671 A CN 201310136671A CN 103230566 B CN103230566 B CN 103230566B
Authority
CN
China
Prior art keywords
parts
chinese medicine
radix
herba
medicine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310136671.6A
Other languages
Chinese (zh)
Other versions
CN103230566A (en
Inventor
王晓素
朱锡祺
朱生樑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of TCM
Original Assignee
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of TCM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of TCM filed Critical Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of TCM
Priority to CN201310136671.6A priority Critical patent/CN103230566B/en
Publication of CN103230566A publication Critical patent/CN103230566A/en
Application granted granted Critical
Publication of CN103230566B publication Critical patent/CN103230566B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relate to a traditional Chinese medical composition for treating cholecystitis cholelithiasis. The composition is prepared by the following raw material medicines as follows: oriental wormwood, Lysimachia christinae Hance, Polygonum cuspidatum, radix curcumae, elecampane and raw fructus aurantii. The invention further relates to a traditional Chinese medical composition for treating cholecystitis cholelithiasis. The composition is prepared by the following raw material medicines as follows: oriental wormwood, Lysimachia christinae Hance, Polygonum cuspidatum, radix curcumae, elecampane, raw fructus aurantii, Corymbose Hedyotis Herb, rheum officinale and corn stigma. The invention further provides an application of the traditional Chinese medical composition. The traditional Chinese medical composition provided by the invention has the advantages that the traditional Chinese medical composition provided by the invention meets the principle of monarch, minister, assistant and guide in all formula, is exact in curative effect for treating cholecystitis cholelithiasis, and can improve symptoms and alleviate pain of patients. The traditional Chinese medical composition is convenient to use and worth applying.

Description

A kind of Chinese medicine composition and application thereof for the treatment of cholecystitis and cholelithiasis
Technical field
The present invention relates to technical field of Chinese medicines, specifically, is a kind of Chinese medicine composition and application thereof for the treatment of cholecystitis and cholelithiasis.
Background technology
Cholecystitis and cholelithiasis is a kind of common clinical, frequently-occurring disease, has course of disease feature long, that repeatedly show effect, and modern medicine thinks that cholecystitis is many due to antibacterial and viral infection, and obstruction of bile duct or pancreatic juice cause to multiple chemical factors such as the anti-streams of biliary tract.Along with people's living standard improves day by day, the change of dietary structure and the increase of job and life stress, the sickness rate of primary disease is in rising trend.Cholecystitis and cholelithiasis has become one of principal disease affecting human health.
Chinese patent literature CN101045116A discloses a kind of Chinese medicine for the treatment of cholecystitis, crude drug by following weight portion is made: 2~4 parts of Herba Artemisiae Scopariaes, 1~2 part of Radix Scutellariae, 0.6~1.3 part of son, 0.6~1.3 part of Radix Et Rhizoma Rhei, 0.6~1.3 part of the Radix Aucklandiae are practiced in river, 0.6~1.3 part of Rhizoma Alismatis, 0.6~1.3 part of Radix Bupleuri, proves the obviously generation of inflammation-inhibiting of this medicine by modern pharmacology experimental technique, and cholecystitis and cholelithiasis model is had to prevention and therapeutical effect.
Summary of the invention
The object of the invention is for deficiency of the prior art, a kind of Chinese medicine composition for the treatment of cholecystitis and cholelithiasis is provided.
One object more of the present invention is that the Chinese medicine composition of another kind for the treatment of cholecystitis and cholelithiasis is provided.
Another object of the present invention is that a kind of application of Chinese medicine composition for the treatment of cholecystitis and cholelithiasis is provided.
For achieving the above object, the technical scheme that the present invention takes is: a kind of Chinese medicine composition for the treatment of cholecystitis and cholelithiasis, described Chinese medicine composition is made up of the crude drug of following weight portion: Herba Artemisiae Scopariae 2-4 part, Herba Lysimachiae 2-4 part, Rhizoma Polygoni Cuspidati 1.5-2 part, Radix Curcumae 1-1.5 part, Radix Aucklandiae 1-1.5 part, raw Fructus Aurantii 1-1.5 part.
Described Chinese medicine composition is made up of the crude drug of following weight portion: Herba Artemisiae Scopariae 2.5-3.5 part, Herba Lysimachiae 2.5-3.5 part, Rhizoma Polygoni Cuspidati 1.7-1.9 part, Radix Curcumae 1.1-1.3 part, Radix Aucklandiae 1.1-1.3 part, raw Fructus Aurantii 1.1-1.3 part.
Described Chinese medicine composition is made up of the crude drug of following weight portion: 3 parts of Herba Artemisiae Scopariaes, 3 parts of Herba Lysimachiaes, 1.8 parts of Rhizoma Polygoni Cuspidati, 1.2 parts of Radix Curcumaes, 1.2 parts of the Radix Aucklandiae, 1.2 parts of raw Fructus Aurantiis.
For realizing above-mentioned second object, the technical scheme that the present invention takes is: a kind of Chinese medicine composition for the treatment of cholecystitis and cholelithiasis, described Chinese medicine composition is made up of the crude drug of following weight portion: Herba Artemisiae Scopariae 2-4 part, Herba Lysimachiae 2-4 part, Rhizoma Polygoni Cuspidati 1.5-2 part, Radix Curcumae 1-1.5 part, Radix Aucklandiae 1-1.5 part, raw Fructus Aurantii 1-1.5 part, Herba Hedyotidis Corymbosae 2-4 part, Radix Et Rhizoma Rhei 0.1-0.5 part, Stigma Maydis 2-4 part.
Described Chinese medicine composition is made up of the crude drug of following weight portion: Herba Artemisiae Scopariae 2.5-3.5 part, Herba Lysimachiae 2.5-3.5 part, Rhizoma Polygoni Cuspidati 1.7-1.9 part, Radix Curcumae 1.1-1.3 part, Radix Aucklandiae 1.1-1.3 part, raw Fructus Aurantii 1.1-1.3 part, Herba Hedyotidis Corymbosae 2.5-3.5 part, Radix Et Rhizoma Rhei 0.2-0.4 part, Stigma Maydis 2.5-3.5 part.
Described Chinese medicine composition is made up of the crude drug of following weight portion: 3 parts of Herba Artemisiae Scopariaes, 3 parts of Herba Lysimachiaes, 1.8 parts of Rhizoma Polygoni Cuspidati, 1.2 parts of Radix Curcumaes, 1.2 parts of the Radix Aucklandiae, 1.2 parts of raw Fructus Aurantiis, 3 parts, Herba Hedyotidis Corymbosae, 0.3 part of Radix Et Rhizoma Rhei, 3 parts of Stigma Maydis.
For realizing above-mentioned the 3rd object, the technical scheme that the present invention takes is: the application of described Chinese medicine composition in the medicine of preparation treatment cholecystitis and cholelithiasis.
The invention has the advantages that:
The full side's compatibility of Chinese medicine composition of the present invention meets Chinese medicine " monarch " principle, and treatment cholecystitis and cholelithiasis determined curative effect, can improve symptom, alleviates patient suffering.Medication is convenient, is worthy to be popularized.
Detailed description of the invention
Below in conjunction with embodiment, detailed description of the invention provided by the invention is elaborated.
The invention provides a kind of Chinese medicine composition one for the treatment of cholecystitis and cholelithiasis, made by the crude drug of following weight portion: Herba Artemisiae Scopariae 2-4 part, Herba Lysimachiae 2-4 part, Rhizoma Polygoni Cuspidati 1.5-2 part, Radix Curcumae 1-1.5 part, Radix Aucklandiae 1-1.5 part, raw Fructus Aurantii 1-1.5 part.
embodiment 1 Chinese medicine composition one
2 parts of Herba Artemisiae Scopariaes, 4 parts of Herba Lysimachiaes, 1.5 parts of Rhizoma Polygoni Cuspidati, 1.5 parts of Radix Curcumaes, 1 part of the Radix Aucklandiae, 1.5 parts of raw Fructus Aurantiis.
embodiment 2 Chinese medicine compositions one
2.2 parts of Herba Artemisiae Scopariaes, 3.7 parts of Herba Lysimachiaes, 1.6 parts of Rhizoma Polygoni Cuspidati, 1.4 parts of Radix Curcumaes, 1.1 parts of the Radix Aucklandiae, 1.4 parts of raw Fructus Aurantiis.
embodiment 3 Chinese medicine compositions one
2.4 parts of Herba Artemisiae Scopariaes, 3.5 parts of Herba Lysimachiaes, 1.7 parts of Rhizoma Polygoni Cuspidati, 1.3 parts of Radix Curcumaes, 1.2 parts of the Radix Aucklandiae, 1.3 parts of raw Fructus Aurantiis.
embodiment 4 Chinese medicine compositions one
2.5 parts of Herba Artemisiae Scopariaes, 3.4 parts of Herba Lysimachiaes, 1.8 parts of Rhizoma Polygoni Cuspidati, 1.2 parts of Radix Curcumaes, 1.3 parts of the Radix Aucklandiae, 1.2 parts of raw Fructus Aurantiis.
embodiment 5 Chinese medicine compositions one
2.6 parts of Herba Artemisiae Scopariaes, 3.2 parts of Herba Lysimachiaes, 1.9 parts of Rhizoma Polygoni Cuspidati, 1.1 parts of Radix Curcumaes, 1.4 parts of the Radix Aucklandiae, 1.1 parts of raw Fructus Aurantiis.
embodiment 6 Chinese medicine compositions one
2.8 parts of Herba Artemisiae Scopariaes, 2.8 parts of Herba Lysimachiaes, 2 parts of Rhizoma Polygoni Cuspidati, 1 part of Radix Curcumae, 1.5 parts of the Radix Aucklandiae, 1 part of raw Fructus Aurantii.
embodiment 7 Chinese medicine compositions one
3 parts of Herba Artemisiae Scopariaes, 3 parts of Herba Lysimachiaes, 1.8 parts of Rhizoma Polygoni Cuspidati, 1.2 parts of Radix Curcumaes, 1.2 parts of the Radix Aucklandiae, 1.2 parts of raw Fructus Aurantiis.
embodiment 8 Chinese medicine compositions one
3.2 parts of Herba Artemisiae Scopariaes, 2.6 parts of Herba Lysimachiaes, 1.9 parts of Rhizoma Polygoni Cuspidati, 1.1 parts of Radix Curcumaes, 1.4 parts of the Radix Aucklandiae, 1.1 parts of raw Fructus Aurantiis.
embodiment 9 Chinese medicine compositions one
3.4 parts of Herba Artemisiae Scopariaes, 2.5 parts of Herba Lysimachiaes, 1.7 parts of Rhizoma Polygoni Cuspidati, 1.2 parts of Radix Curcumaes, 1.5 parts of the Radix Aucklandiae, 1.3 parts of raw Fructus Aurantiis.
embodiment 10 Chinese medicine compositions one
3.5 parts of Herba Artemisiae Scopariaes, 2.4 parts of Herba Lysimachiaes, 1.6 parts of Rhizoma Polygoni Cuspidati, 1.3 parts of Radix Curcumaes, 1.2 parts of the Radix Aucklandiae, 1.4 parts of raw Fructus Aurantiis.
embodiment 11 Chinese medicine compositions one
3.8 parts of Herba Artemisiae Scopariaes, 2.2 parts of Herba Lysimachiaes, 1.5 parts of Rhizoma Polygoni Cuspidati, 1.4 parts of Radix Curcumaes, 1.1 parts of the Radix Aucklandiae, 1.5 parts of raw Fructus Aurantiis.
embodiment 12 Chinese medicine compositions one
4 parts of Herba Artemisiae Scopariaes, 2 parts of Herba Lysimachiaes, 1.8 parts of Rhizoma Polygoni Cuspidati, 1.5 parts of Radix Curcumaes, 1 part of the Radix Aucklandiae, 1.2 parts of raw Fructus Aurantiis.
The present invention also provides a kind of Chinese medicine composition two for the treatment of cholecystitis and cholelithiasis, is made up of the crude drug of following weight portion: Herba Artemisiae Scopariae 2-4 part, Herba Lysimachiae 2-4 part, Rhizoma Polygoni Cuspidati 1.5-2 part, Radix Curcumae 1-1.5 part, Radix Aucklandiae 1-1.5 part, raw Fructus Aurantii 1-1.5 part, Herba Hedyotidis Corymbosae 2-4 part, Radix Et Rhizoma Rhei 0.1-0.5 part, Stigma Maydis 2-4 part.
embodiment 13 Chinese medicine compositions two
2 parts of Herba Artemisiae Scopariaes, 4 parts of Herba Lysimachiaes, 1.5 parts of Rhizoma Polygoni Cuspidati, 1.5 parts of Radix Curcumaes, 1 part of the Radix Aucklandiae, 1.5 parts of raw Fructus Aurantiis, 2 parts, Herba Hedyotidis Corymbosae, 0.5 part of Radix Et Rhizoma Rhei, 2 parts of Stigma Maydis.
embodiment 14 Chinese medicine compositions two
2.2 parts of Herba Artemisiae Scopariaes, 3.7 parts of Herba Lysimachiaes, 1.6 parts of Rhizoma Polygoni Cuspidati, 1.4 parts of Radix Curcumaes, 1.1 parts of the Radix Aucklandiae, 1.4 parts of raw Fructus Aurantiis, 2.2 parts, Herba Hedyotidis Corymbosae, 0.4 part of Radix Et Rhizoma Rhei, 2.2 parts of Stigma Maydis.
embodiment 15 Chinese medicine compositions two
2.4 parts of Herba Artemisiae Scopariaes, 3.5 parts of Herba Lysimachiaes, 1.7 parts of Rhizoma Polygoni Cuspidati, 1.3 parts of Radix Curcumaes, 1.2 parts of the Radix Aucklandiae, 1.3 parts of raw Fructus Aurantiis, 2.4 parts, Herba Hedyotidis Corymbosae, 0.3 part of Radix Et Rhizoma Rhei, 2.4 parts of Stigma Maydis.
embodiment 16 Chinese medicine compositions two
2.5 parts of Herba Artemisiae Scopariaes, 3.4 parts of Herba Lysimachiaes, 1.8 parts of Rhizoma Polygoni Cuspidati, 1.2 parts of Radix Curcumaes, 1.3 parts of the Radix Aucklandiae, 1.2 parts of raw Fructus Aurantiis, 2.5 parts, Herba Hedyotidis Corymbosae, 0.2 part of Radix Et Rhizoma Rhei, 2.5 parts of Stigma Maydis.
embodiment 17 Chinese medicine compositions two
2.6 parts of Herba Artemisiae Scopariaes, 3.2 parts of Herba Lysimachiaes, 1.9 parts of Rhizoma Polygoni Cuspidati, 1.1 parts of Radix Curcumaes, 1.4 parts of the Radix Aucklandiae, 1.1 parts of raw Fructus Aurantiis, 2.6 parts, Herba Hedyotidis Corymbosae, 0.1 part of Radix Et Rhizoma Rhei, 2.6 parts of Stigma Maydis.
embodiment 18 Chinese medicine compositions two
2.8 parts of Herba Artemisiae Scopariaes, 2.8 parts of Herba Lysimachiaes, 2 parts of Rhizoma Polygoni Cuspidati, 1 part of Radix Curcumae, 1.5 parts of the Radix Aucklandiae, 1 part of raw Fructus Aurantii, 2.8 parts, Herba Hedyotidis Corymbosae, 0.2 part of Radix Et Rhizoma Rhei, 2.8 parts of Stigma Maydis.
embodiment 19 Chinese medicine compositions two
3 parts of Herba Artemisiae Scopariaes, 3 parts of Herba Lysimachiaes, 1.8 parts of Rhizoma Polygoni Cuspidati, 1.2 parts of Radix Curcumaes, 1.2 parts of the Radix Aucklandiae, 1.2 parts of raw Fructus Aurantiis, 3 parts, Herba Hedyotidis Corymbosae, 0.3 part of Radix Et Rhizoma Rhei, 3 parts of Stigma Maydis.
embodiment 20 Chinese medicine compositions two
3.2 parts of Herba Artemisiae Scopariaes, 2.6 parts of Herba Lysimachiaes, 1.9 parts of Rhizoma Polygoni Cuspidati, 1.1 parts of Radix Curcumaes, 1.4 parts of the Radix Aucklandiae, 1.1 parts of raw Fructus Aurantiis, 3.2 parts, Herba Hedyotidis Corymbosae, 0.4 part of Radix Et Rhizoma Rhei, 3.2 parts of Stigma Maydis.
embodiment 21 Chinese medicine compositions two
3.4 parts of Herba Artemisiae Scopariaes, 2.5 parts of Herba Lysimachiaes, 1.7 parts of Rhizoma Polygoni Cuspidati, 1.2 parts of Radix Curcumaes, 1.5 parts of the Radix Aucklandiae, 1.3 parts of raw Fructus Aurantiis, 3.4 parts, Herba Hedyotidis Corymbosae, 0.5 part of Radix Et Rhizoma Rhei, 3.4 parts of Stigma Maydis.
embodiment 22 Chinese medicine compositions two
3.5 parts of Herba Artemisiae Scopariaes, 2.4 parts of Herba Lysimachiaes, 1.6 parts of Rhizoma Polygoni Cuspidati, 1.3 parts of Radix Curcumaes, 1.2 parts of the Radix Aucklandiae, 1.4 parts of raw Fructus Aurantiis, 3.5 parts, Herba Hedyotidis Corymbosae, 0.3 part of Radix Et Rhizoma Rhei, 3.5 parts of Stigma Maydis.
embodiment 23 Chinese medicine compositions two
3.8 parts of Herba Artemisiae Scopariaes, 2.2 parts of Herba Lysimachiaes, 1.5 parts of Rhizoma Polygoni Cuspidati, 1.4 parts of Radix Curcumaes, 1.1 parts of the Radix Aucklandiae, 1.5 parts of raw Fructus Aurantiis, 3.8 parts, Herba Hedyotidis Corymbosae, 0.2 part of Radix Et Rhizoma Rhei, 3.8 parts of Stigma Maydis.
embodiment 24 Chinese medicine compositions two
4 parts of Herba Artemisiae Scopariaes, 2 parts of Herba Lysimachiaes, 1.8 parts of Rhizoma Polygoni Cuspidati, 1.5 parts of Radix Curcumaes, 1 part of the Radix Aucklandiae, 1.2 parts of raw Fructus Aurantiis, 4 parts, Herba Hedyotidis Corymbosae, 0.3 part of Radix Et Rhizoma Rhei, 4 parts of Stigma Maydis.
the preparation of embodiment 25 Chinese medicine composition decoctions
Adopt the manufacture method of Chinese medicine decoction routine, get the arbitrary described Chinese medicine composition of embodiment 1-24 and decoct with water into decoction.
the preparation of embodiment 26 Chinese medicine composition tablets/capsule
Get the arbitrary described Chinese medicine composition of embodiment 1-24, add 6-10 times of water gaging, decoct 1-3 hour, leach medicine juice.Add again 6-10 times of water gaging, decoct 0.5-2 hour, leach medicine juice, merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add concentrated solution 2-3 and doubly measure ethanol, stir precipitation and spend the night.Get supernatant, be concentrated into thick extractum; Add pharmaceutical aids, vacuum drying, pulverizes and granulates, and is pressed into tablet or fills encapsulated.
the preparation of embodiment 27 Chinese medicine composition composition granules
Get the arbitrary described Chinese medicine composition of embodiment 1-24, add 10 times of water gagings, decoct 2 hours, leach medicine juice.Add again 8 times of water gagings, decoct 1 hour, leach medicine juice, merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add 2 times of amount ethanol of concentrated solution, stir precipitation and spend the night.Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, granulate, dry, granulate, obtains granule, subpackage 5g/ bag.
the preparation of embodiment 28 Chinese medicine composition mixture/oral liquid/syrups
Get the arbitrary described Chinese medicine composition of embodiment 1-24, add 10 times of water gagings, decoct 2 hours, leach medicine juice.Add again 8 times of water gagings, decoct 1 hour, leach medicine juice, merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add 2 times of amount ethanol of concentrated solution, stir precipitation and spend the night.Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids (white sugar, Mel, benzene first propanoic acid or ethyl hydroxybenzoate etc.), make mixture, oral liquid or syrup.
the clinical experiment of embodiment 29 traditional Chinese medicine composition for treating cholecystitis and cholelithiasis
1 data and method
1.1 physical data
Select the Gastroenterology dept.'s outpatient service of 2010-2011 hospital and medical cholecystitis and cholelithiasis patient 150 examples of in-patient department, all meet " new Chinese medicine guideline of clinical investigations " and determine diagnosis.Inclusive criteria: meet the patient of chronic cholecystitis diagnosis and Standards of Chinese Medical Syndrome Differentiation, can include test case in.Exclusion standard: (1) does not meet inclusive criteria; (2) discomforts such as the side of body rib distension pain of being brought out by the factor such as Drug or other diseases.(3) merge intentionally, the serious disease such as brain, lung, kidney.(4) gestation or women breast-feeding their children, those who are allergic to this drug.(5) severe cholecystitis: acute suppuration cholecystitis, acute gangrenous cholecystitis, acute obstructive suppurative cholangitis, the concurrent diffuse peritonitis person of perforation of gallbladder.(6) take other similar drugs person simultaneously.
150 examples are included patient in, by table of random number method, are divided into one group for the treatment of, treatment two groups and matched group with 2:2:1 ratio:
Treat one group of 60 example, 1 example that comes off, totally 59 examples, male's 30 examples, women's 29 examples, 18-29 year 13 people, 30-49 year 27 people, 50-65 year 19 people, patient's course of disease <1 11 people, 1-5 28 people, 5-10 20 people;
Treat two group of 60 example, 1 example that comes off, totally 59 examples, male's 31 examples, women's 28 examples, 18-29 year 12 people, 30-49 year 28 people, 50-65 year 19 people, patient's course of disease <1 10 people, 1-5 30 people, 5-10 19 people;
Matched group 30 examples, 2 examples that come off, totally 28 examples, wherein male's 15 examples, women's 13 examples, 18-29 year 5 people, 30-49 year 13 people, 50-65 year 10 people, patient's course of disease <1 4 people, 1-5 14 people, 5-10 10 people.Three groups of case physical data (sex, age, the course of disease) comparing difference not statistically significant.
1.2 Therapeutic Method
Treat one group of oral Chinese medicine composition one (with reference to embodiment 7 and 25 preparations), every day 2-4 time; Treat two groups of oral Chinese medicine compositions two (with reference to embodiment 19 and 25 preparations), every day 2-4 time; The oral DANNING PIAN of matched group (being produced main component Radix Et Rhizoma Rhei, Rhizoma Polygoni Cuspidati, Pericarpium Citri Reticulatae Viride, Pericarpium Citri Reticulatae, Radix Curcumae, Fructus Crataegi, Rhizoma Imperatae by Shanghai and xanthate industry), 5 tablets/time, every day three times.Treat 8 weeks.Period in a medicine is avoided greasy, irritative food, work and rest rule.
1.3 observation index and method
1.3.1 clinical symptoms integral estimation: before treatment, carry out clinical symptoms integral estimation one time, rear weekly.
1.3.2 lab index: hematuria stool routine, electrocardiogram, B ultrasonic and ALT, serum creatinine.Before treatment, once, rear every surrounding is carried out ALT, serum creatinine inspection to contained item inspection, finishes rear check hematuria stool routine, electrocardiogram and B ultrasonic the course for the treatment of.B ultrasonic result before and after contrast therapy, observes the change of calculus size, gallbladder wall thickness.
1.4 criterion of therapeutical effect
Formulate with reference to " new Chinese medicine clinical research principle ".Recovery from illness: after finishing the course for the treatment of, symptom and sign disappears, and ultrasound diagnosis gallbladder size and wall thickness are normal; Effective: after finishing the course for the treatment of, symptom integral reduces 2 grades, and ultrasound diagnosis gallbladder size and wall thickness obviously improve; Effective: after finishing the course for the treatment of, symptom integral reduces 1 grade, and ultrasound diagnosis gallbladder size and wall thickness are improved; Invalid: do not reach above-mentioned standard person, ultrasound diagnosis gallbladder size still increases, wall thickness, crude.
1.5 statistical method
Adopt SPSS15.0 statistical software to carry out computational analysis, measurement data adopts t inspection, and enumeration data adopts X 2 test, and P<0.05 is that difference has statistical significance.
2 results
The clinical efficacy Epidemiological Analysis by statistics after one group, treatment two groups and treatment of control group is treated in 2.1 therapeutic evaluatioies, and the Different therapeutical effect of three groups has statistical significance (P<0.05), treat one group and treat two groups and be better than matched group (table 1).
The comparison [example (%)] of three groups of clinical efficacies of table 1
Group Number of cases Effective Effectively Invalid Total effective rate (%)
Treat one group 59 34(57.6) 19(32.2) 6(10.2) 89.8
Treat two groups 59 41(70.0) 15(24.8) 3(5.2) 94.8
Matched group 28 15(55.8) 7(23.6) 6(20.6) 79.4
2.2 untoward reaction: three groups all do not occur untoward reaction during treating.
3 discuss
Modern medicine thinks that cholecystitis is many due to antibacterial and viral infection, obstruction of bile duct or pancreatic juice cause that to chemical factors such as the anti-streams of biliary tract the bile that gallbladder inflammation sexually transmitted disease (STD) becomes, biliary drainage is smooth, not concentrated stimulates gallbladder mucosa, cause secretion to increase, intracavity is pressed and is increased, in addition gall bladder emptying postpones, self purification weakens the infringement that has more increased the weight of cyst wall, thereby is more conducive to the growth of antibacterial, so vicious cycle.
Motherland's medical science claims that gallbladder is " extraordinary Fu-organ ", has " full and unreal, also hide and also rush down ", to lead to as suitable feature, thinks " receptor of institute at his mansion, all to turbid thing, the refined juice that only gallbladder is subject to the five internal organs also ".Though without " cholecystitis ", according to its symptom, can be attributed to motherland's medical science " gallbladder-distention ", " hypochondriac pain " category.Jing-Yue Complete Works is pointed out: " disease of hypochondriac pain, this genus liver and gall two warps, with the arteries and veins of two warps, therefore all follow the side of body also." " opinion that Ling Shu Miraculous Pivot or Divine Axis is swollen " " gallbladder-distention person, pain over the hypochondrium is swollen, bitter in mouthful, sighing frequently ".How primary disease disease located in liver gallbladder, cause disorder of QI movement by exopathogen internal injury, and QI stagnation of the liver and galibladder is violated and taste, and transporting and transforming function of the spleen and stomach is unfavorable, and endogenous damp formation is strongly fragrant in damp, and for a long time and heat-transformation, damp-heat accumulation, hinders in side of body network.The present invention's research is accumulating rich experience aspect treatment chronic cholecystitis, cholelithiasis, think gallbladder-heat pent-up, it is this sick the important pathogenesis that irritability is not dredged, treatment should be taking clearing heat secreting bile, dispersing the stagnated live-QI to relieve the stagnation of QI as main, sum up Chinese medicine composition one of the present invention and the Chinese medicine composition two experience prescription as treatment primary disease, in side, contained Herba Lysimachiae has the Huang of dispelling that helps digestion, the effect of clearing away heat-damp and promoting diuresis.The logical intestinal of internal organs, falls in Radix Et Rhizoma Rhei energy clearing away heat-fire.Herba Artemisiae Scopariae clearing away damp-heat, jaundice eliminating subcutaneous ulcer.Above-mentioned Chinese medicine still can promote bile secretion, increases bile solids, bile acid and bilirubinic output.Result of study demonstration of the present invention, Chinese medicine composition one of the present invention and Chinese medicine composition two are treated cholecystitis and cholelithiasis determined curative effect, can improve symptom, alleviate patient suffering.Medication is convenient, is worthy to be popularized.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, do not departing under the prerequisite of the inventive method; can also make some improvement and supplement, these improvement and the supplementary protection scope of the present invention that also should be considered as.

Claims (7)

1. treat the Chinese medicine composition of cholecystitis and cholelithiasis for one kind, it is characterized in that, described Chinese medicine composition is made up of the crude drug of following weight portion: Herba Artemisiae Scopariae 2-4 part, Herba Lysimachiae 2-4 part, Rhizoma Polygoni Cuspidati 1.5-2 part, Radix Curcumae 1-1.5 part, Radix Aucklandiae 1-1.5 part, raw Fructus Aurantii 1-1.5 part.
2. Chinese medicine composition according to claim 1, it is characterized in that, described Chinese medicine composition is made up of the crude drug of following weight portion: Herba Artemisiae Scopariae 2.5-3.5 part, Herba Lysimachiae 2.5-3.5 part, Rhizoma Polygoni Cuspidati 1.7-1.9 part, Radix Curcumae 1.1-1.3 part, Radix Aucklandiae 1.1-1.3 part, raw Fructus Aurantii 1.1-1.3 part.
3. Chinese medicine composition according to claim 1, is characterized in that, described Chinese medicine composition is made up of the crude drug of following weight portion: 3 parts of Herba Artemisiae Scopariaes, 3 parts of Herba Lysimachiaes, 1.8 parts of Rhizoma Polygoni Cuspidati, 1.2 parts of Radix Curcumaes, 1.2 parts of the Radix Aucklandiae, 1.2 parts of raw Fructus Aurantiis.
4. treat the Chinese medicine composition of cholecystitis and cholelithiasis for one kind, it is characterized in that, described Chinese medicine composition is made up of the crude drug of following weight portion: Herba Artemisiae Scopariae 2-4 part, Herba Lysimachiae 2-4 part, Rhizoma Polygoni Cuspidati 1.5-2 part, Radix Curcumae 1-1.5 part, Radix Aucklandiae 1-1.5 part, raw Fructus Aurantii 1-1.5 part, Herba Hedyotidis Corymbosae 2-4 part, Radix Et Rhizoma Rhei 0.1-0.5 part, Stigma Maydis 2-4 part.
5. Chinese medicine composition according to claim 4, it is characterized in that, described Chinese medicine composition is made up of the crude drug of following weight portion: Herba Artemisiae Scopariae 2.5-3.5 part, Herba Lysimachiae 2.5-3.5 part, Rhizoma Polygoni Cuspidati 1.7-1.9 part, Radix Curcumae 1.1-1.3 part, Radix Aucklandiae 1.1-1.3 part, raw Fructus Aurantii 1.1-1.3 part, Herba Hedyotidis Corymbosae 2.5-3.5 part, Radix Et Rhizoma Rhei 0.2-0.4 part, Stigma Maydis 2.5-3.5 part.
6. Chinese medicine composition according to claim 4, it is characterized in that, described Chinese medicine composition is made up of the crude drug of following weight portion: 3 parts of Herba Artemisiae Scopariaes, 3 parts of Herba Lysimachiaes, 1.8 parts of Rhizoma Polygoni Cuspidati, 1.2 parts of Radix Curcumaes, 1.2 parts of the Radix Aucklandiae, 1.2 parts of raw Fructus Aurantiis, 3 parts, Herba Hedyotidis Corymbosae, 0.3 part of Radix Et Rhizoma Rhei, 3 parts of Stigma Maydis.
7. the application in the medicine of preparation treatment cholecystitis and cholelithiasis according to the arbitrary described Chinese medicine composition of claim 1-6.
CN201310136671.6A 2013-04-19 2013-04-19 Traditional Chinese medical composition for treating cholecystitis cholelithiasis and application thereof Active CN103230566B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310136671.6A CN103230566B (en) 2013-04-19 2013-04-19 Traditional Chinese medical composition for treating cholecystitis cholelithiasis and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310136671.6A CN103230566B (en) 2013-04-19 2013-04-19 Traditional Chinese medical composition for treating cholecystitis cholelithiasis and application thereof

Publications (2)

Publication Number Publication Date
CN103230566A CN103230566A (en) 2013-08-07
CN103230566B true CN103230566B (en) 2014-11-26

Family

ID=48878681

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310136671.6A Active CN103230566B (en) 2013-04-19 2013-04-19 Traditional Chinese medical composition for treating cholecystitis cholelithiasis and application thereof

Country Status (1)

Country Link
CN (1) CN103230566B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104606620A (en) * 2015-02-01 2015-05-13 徐鸿刚 Traditional Chinese medicine for treating cholecystitis
CN104547721A (en) * 2015-02-05 2015-04-29 王昌荣 Traditional Chinese medicine for treating cholecystitis
CN109224034A (en) * 2018-11-13 2019-01-18 谭龙 A kind of Hepatoprotective cholagogue Nieron Capsules and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1150041C (en) * 2000-09-26 2004-05-19 兴运实业(成都)有限公司 Multi-source infrared energy therapy room
CN101274087B (en) * 2008-05-14 2011-04-20 刘庆常 Chinese medicine decoction for invigorating gallbladder and removing gall-stone

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1052163C (en) * 1996-09-24 2000-05-10 秦应中 Chinese patent medicine for curing gallstones and kidney stones

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1150041C (en) * 2000-09-26 2004-05-19 兴运实业(成都)有限公司 Multi-source infrared energy therapy room
CN101274087B (en) * 2008-05-14 2011-04-20 刘庆常 Chinese medicine decoction for invigorating gallbladder and removing gall-stone

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
刘志勇.利胆法在胃肠病治疗中的应用体会.《河北中医》.1998,第20卷(第01期), *
利胆法在胃肠病治疗中的应用体会;刘志勇;《河北中医》;19981231;第20卷(第01期);26-27 *

Also Published As

Publication number Publication date
CN103230566A (en) 2013-08-07

Similar Documents

Publication Publication Date Title
CN101700358A (en) Medicine for treating acute and chronic nonspecific ulcerative colitis and preparation method thereof
CN103263615A (en) Traditional Chinese medicine preparation for treating stomach illness, enteritis and cholecystitis and preparation method thereof
CN1720943A (en) A kind of medicinal composition for the treatment of hyperuricemia and urate nephropathy
CN103230566B (en) Traditional Chinese medical composition for treating cholecystitis cholelithiasis and application thereof
CN103110816B (en) Chinese herba preparation for treating chronic ulcerative colitis
CN102225190A (en) Traditional Chinese preparation for treating chronic colitis
CN105832991A (en) Traditional Chinese medicine composition for treating gastritis
CN102657811B (en) Orally administered liquid for treating canker sore
CN101073648A (en) Method for treating senile constipation
CN103110905A (en) Traditional Chinese medical preparation for treating cholecystitis with stagnation of liver qi and spleen deficiency
CN102302744B (en) Chinese medicinal preparation for treating chronic cholecystitis
CN100577199C (en) Application of stomachic pill with cyperus and amomum
CN111228367A (en) Traditional Chinese medicine external lotion for treating infantile anaphylactoid purpura and preparation method thereof
CN1879722A (en) A medicine for treating rheumatic arthritis
CN103520638B (en) A kind of Traditional Chinese medicine compound composition for the treatment of prostate hyperplasia and preparation method thereof and application thereof
CN103845689A (en) External application medicine for treating benign prostatic hyperplasia
CN102258589B (en) Deer blood medicinal wine for treating rheumatoid arthritis
CN102988945B (en) Traditional Chinese medicine prescription for treating enteritis
CN103536745A (en) Traditional Chinese medicinal watered pills for treating hyperplasia of mammary glands
Liu et al. A case of oral lichen planus treated by clearing phlegm and heat
CN105434988A (en) Traditional Chinese medicine composition for treating neurodermatitis
CN103263516B (en) Medicine for treating cholecystitis
CN104001077A (en) Traditional Chinese medicine composition for treating urinary tract infection and application thereof
CN102423454A (en) Chinese medicinal preparation for treating chronic cholecystitis
CN104857329A (en) Clysis liquid for curing ulcerative colitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant